The table below shows Monte Rosa Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$22.80M
$42.00M
-$43.80M
-$92.47M
-$59.36M
-$23.05M
Capital expenditure
$4.70M
$3.99M
$19.04M
$12.91M
$9.73M
$3.39M
Investing cash flow
-$101.83M
-$44.45M
$88.80M
-$219.22M
-$9.65M
-$3.39M
Dividends paid
$0.00
$0.00
$0.00
$0.00
GLUE operating cash flow (10-K history)
Monte Rosa Therapeutics, Inc. reported operating cash flow of -$22.80M for fiscal year 2025. That is down 154.3% from $42.00M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow grew from -$23.05M (FY 2020) to -$22.80M. Figures come from the company's audited annual reports as filed with the SEC.
